Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Journal of Mammary Gland Biology and Neoplasia

Issue 2/2011

Transforming Growth Factor-beta

Content (10 Articles)

Preface

TGFβ Biology in Breast: 15 Years On

Mary Helen Barcellos-Hoff

Choreographing Metastasis to the Tune of LTBP

Anupama Chandramouli, Julia Simundza, Alicia Pinderhughes, Pamela Cowin

When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene

Amy Chow, Carlos L. Arteaga, Shizhen Emily Wang

TGFBR1 Signaling and Breast Cancer

Lakisha Moore-Smith, Boris Pasche

Open Access

TGF-β Signaling in Breast Cancer Cell Invasion and Bone Metastasis

Yvette Drabsch, Peter ten Dijke

Crosstalk of TGF-β and Estrogen Receptor Signaling in Breast Cancer

Arja M. Band, Marikki Laiho

The Role of Activin in Mammary Gland Development and Oncogenesis

Karen A. Dunphy, Alan L. Schneyer, Mary J. Hagen, D. Joseph Jerry

Noncanonical TGF-β Signaling During Mammary Tumorigenesis

Jenny G. Parvani, Molly A. Taylor, William P. Schiemann

Consequences of Epithelial or Stromal TGFβ1 Depletion in the Mammary Gland

David H. Nguyen, Haydeliz Martinez-Ruiz, Mary Helen Barcellos-Hoff

Wnt5a as an Effector of TGFβ in Mammary Development and Cancer

Rosa Serra, Stephanie L. Easter, Wen Jiang, Sarah E. Baxley

Apr 11
Issue: 1/2011
Hereditary Breast Cancer
Sep 11
Issue: 3/2011
Tumor Suppressors: Heroes and Villains?

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits